About Forest Laboratories (NYSE:FRX)
Forest Laboratories, Inc. (Forest), develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company's products include Namenda, a N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; Bystolic, a beta-blocker for the treatment of hypertension; Linzess, a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza, a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and Viibryd, a SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with depressive disorder (MDD). In February 2014, it acquired Aptalis. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Forest Laboratories (NYSE:FRX) Frequently Asked Questions
What is Forest Laboratories' stock symbol?
Forest Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "FRX."
Who are some of Forest Laboratories' key competitors?
Some companies that are related to Forest Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), Novo Nordisk A/S (NVO), Amgen (AMGN), Sanofi (SNY), Bristol-Myers Squibb (BMY), Eli Lilly and (LLY), Abbott Laboratories (ABT), GlaxoSmithKline (GSK), Celgene (CELG), AstraZeneca (AZN), GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG), Beximco Pharmaceuticals (BXP) and Shire (SHP).
How do I buy Forest Laboratories stock?
Shares of Forest Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Forest Laboratories?
Forest Laboratories' mailing address is 909 3rd Ave, NEW YORK, NY 10022-4731, United States. The healthcare company can be reached via phone at +1-212-4217850.
MarketBeat Community Rating for Forest Laboratories (FRX)MarketBeat's community ratings are surveys of what our community members think about Forest Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Forest Laboratories (NYSE:FRX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Forest Laboratories (NYSE:FRX) Earnings History and Estimates Chart
Forest Laboratories (NYSE FRX) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/29/2014||Q414||$0.45||$0.87||$959.00 million||$1.05 million||View||N/A|
|1/21/2014||Q314||$0.06||$0.27||$827.25 million||$846.80 million||View||N/A|
|7/23/2013||Q1 2014||$0.09||$0.28||$798.41 million||$796.90 million||View||N/A|
|4/23/2013||Q4 2013||$0.16||$0.17||$807.00 million||$783.20 million||View||N/A|
|1/15/2013||Q3 2013||($0.14)||($0.21)||$765.94 million||$678.00 million||View||N/A|
Forest Laboratories (NYSE:FRX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Forest Laboratories (NYSE:FRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Forest Laboratories (NYSE FRX) Insider Trading and Institutional Ownership History
Forest Laboratories (NYSE FRX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/27/2014||Howard Solomon||Director||Sell||250,000||$65.41||$16,352,500.00|| |
|1/23/2014||Howard Solomon||Director||Sell||250,000||$67.13||$16,782,500.00|| |
|1/22/2014||Jerome Lynch||SVP||Sell||135,625||$67.28||$9,124,850.00|| |
|8/26/2013||Lawrence Olanoff||Director||Sell||1,104||$42.96||$47,427.84|| |
|8/21/2013||Perier Francis, Jr.||CFO||Sell||12,000||$43.00||$516,000.00|| |
|9/4/2012||Carl C Icahn||Major Shareholder||Buy||86,848||$34.64||$3,008,414.72|| |
|8/29/2012||Carl C Icahn||Major Shareholder||Buy||331,406||$34.65||$11,483,217.90|| |
|8/24/2012||Carl C Icahn||Major Shareholder||Buy||1,343,837||$34.57||$46,456,445.09|| |
|8/21/2012||Carl C Icahn||Major Shareholder||Buy||1,962,011||$34.18||$67,061,535.98|| |
Forest Laboratories (NYSE FRX) News Headlines
Forest Laboratories (NYSE:FRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Forest Laboratories (NYSE:FRX) Income Statement, Balance Sheet and Cash Flow Statement
Forest Laboratories (NYSE FRX) Stock Chart for Friday, December, 15, 2017